Search

Your search keyword '"Mooradian, Meghan J"' showing total 201 results

Search Constraints

Start Over You searched for: Author "Mooradian, Meghan J" Remove constraint Author: "Mooradian, Meghan J"
201 results on '"Mooradian, Meghan J"'

Search Results

1. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

3. Cryoablation and post-progression immune checkpoint inhibition in metastatic melanoma: a phase II trial

7. Immune-related adverse events requiring hospitalization in patients with lung cancer: implications and insights.

9. Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy

13. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0

14. Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study

17. What to Do When Anti-PD-1 Therapy Fails in Patients With Melanoma

19. Dose‐escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF ‐mutant solid tumors

22. Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer

23. Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma

24. Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma

25. Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study

26. Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer

27. Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma

29. Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy

30. Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer

31. Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors

32. Temporal Trends in Inpatient Oncology Census Before and During the COVID-19 Pandemic and Rates of Nosocomial COVID-19 Among Patients with Cancer at a Large Academic Center

34. Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018

35. Coronavirus Disease 2019 Infection in a Patient Population with Lung Cancer: Incidence, Presentation, and Alternative Diagnostic Considerations

36. A multicenter characterization of hepatitis associated with immune checkpoint inhibitors

38. The Art of Oncology: COVID-19 Era

40. Immune checkpoint inhibitor-associated celiac disease

44. Prognostic implications of co-occurring dermatologic and gastrointestinal toxicity from immune checkpoint inhibition therapy for advanced malignancies: A retrospective cohort study

46. Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer

47. Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy

48. The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors

Catalog

Books, media, physical & digital resources